Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialEugenio Mercuri, A. Nascimento, E. Niks et al.|The Lancet Neurology|2024Cited by 128
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trialThomas O. Crawford, Barbara Steinborn, Eugenio Mercuri et al.|The Lancet Neurology|2025Cited by 22
Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History ComparisonsCraig M. McDonald, Michela Guglieri, Dragana Vučinić et al.|Annals of Clinical and Translational Neurology|2025Cited by 12
Givinostat in Duchenne Muscular Dystrophy: Natural history comparison applying propensity score matchingDavid Gómez‐Andrés, P. Bettica, Mercedes López Lobato et al.|Nervenheilkunde|2025Cited by 0